PF Equity Holdings 2 B.V. - Mar 31, 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
10%+ Owner
Signature
/s/Susan E. Grant, Attorney-in-fact on behalf of PF Equity Holdings 2 B.V.
Stock symbol
ALLO
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 04:44 PM
Previous filing
Sep 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Other $0 -22M -100% $0.00* 0 Mar 31, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

PF Equity Holdings 2 B.V. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Shares transferred to its parent entity, Pfizer Inc., for no cash consideration.